arbaclofen Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Arbaclofen placarbil is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.   Wikipedia

Chemistry

  • SMILES: CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C
  • InChIKey: JXTAALBWJQJLGN-KSSFIOAISA-N
  • Mol. Mass: 399.87
  • ALogP: 3.81
  • ChEMBL Molecules:
    arbaclofen placarbil  
    arbaclofen  
More Chemistry

Pharmacology

Alternative names

4-chloro-beta-((((2-methyl-1-(2-methyl-1-oxopropoxy)propoxy)carbonyl)amino)methyl)benzenepropanoic acid | arbaclofen | arbaclofen hydrochloride | arbaclofen placarbil | (r)-4-amino-3-(4-chlorophenyl)butan­oic acid | (r)-baclofen | stx209 | xp19986 | xp-19986

Organizations (28)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Alcoholism (Phase 2)

Autism Spectrum Disorder (Phase 3)

Back Pain (Phase 2)

Fragile X Syndrome (Phase 3)

Gastroesophageal Reflux (Phase 2)

Healthy Volunteers (Phase 1)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 3)

Spermatozoa (Phase 3)

Substance Withdrawal Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue